Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price fell 22.7% during mid-day trading on Thursday . The stock traded as low as GBX 10.36 ($0.13) and last traded at GBX 10.44 ($0.13). 1,612,554 shares were traded during mid-day trading, an increase of 135% from the average session volume of 685,754 shares. The stock had previously closed at GBX 13.50 ($0.17).
Scancell Price Performance
The company has a debt-to-equity ratio of 61.41, a quick ratio of 13.01 and a current ratio of 3.42. The company has a market capitalization of £103.42 million, a PE ratio of -1,098.80 and a beta of 0.35. The stock has a 50 day moving average price of GBX 13.90 and a two-hundred day moving average price of GBX 13.61.
About Scancell
(
Get Free Report)
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Featured Articles
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
